Assessment of Functional Capacity of Immune System in Patients
with Multiple Sclerosis using QuantiFERON Monitor

J 2023

Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor

PAVELEK, Zbysek, Ondrej SOUCEK, Jan KREJSEK, Ilona SEJKOROVA, Oldrich VYSATA et. al.

Základní údaje

Originální název

Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor

Autoři

PAVELEK, Zbysek (203 Česká republika), Ondrej SOUCEK (203 Česká republika), Jan KREJSEK (203 Česká republika), Ilona SEJKOROVA (203 Česká republika), Oldrich VYSATA (203 Česká republika), Blanka KLIMOVA (203 Česká republika), Francesco ANGELUCCI, Pavel ŠTOURAČ (203 Česká republika, domácí), Martin VALIS (203 Česká republika), Marek PETERKA (203 Česká republika), Lukas SOBISEK (203 Česká republika) a Michal NOVOTNY (203 Česká republika, garant)

Vydání

Journal of Immunology Research, London, Hindawi, 2023, 2314-8861

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.100 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133352

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1155/2023/4653627

UT WoS

000970514700001

Klíčová slova anglicky

Multiple Sclerosis; Immune System; QuantiFERON Monitor

Štítky

14110221, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 1. 2024 13:12, Mgr. Tereza Miškechová

Anotace

V originále

Background. The QuantiFERON (R)-Monitor (QFM) is an assay that measures interferon-gamma production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms of multiple sclerosis (MS), relapsing-remitting form treated with fingolimod (fMS) and secondarily progressive form not treated pharmacologically (pMS), and in healthy controls (HC). We hypothesized that IFN-gamma levels would be lower in those subjects who are relatively more immunosuppressed and higher in those with normal or activated immune function. Methods. This single-center observational study was conducted from November 2020 to October 2021 and compared results in three groups of patients: 86 healthy controls, 96 patients with pMS, and 78 fMS. Combination of lyophilized stimulants was added to 1 ml heparinized whole blood within 8 hr of collection. Plasmatic IFN-gamma was measured using the ELISA kit for the QFM and data were obtained in IU/ml. Results. The results showed that controls had nearly 2-fold higher levels of IFN-gamma (QFM score) in median (q25, q75) 228.00 (112.20, 358.67) than the MS patient groups: pMS 144.80 (31.23, 302.00); fMS 130.50 (39.95, 217.07) which is statistically significant difference P-value: HC vs. pMS = 0.0071; HC vs. fMS = 0.0468. This result was also confirmed by a validation analysis to exclude impact of variable factors, such as disease duration and Expanded Disability Status Scale scores. Conclusions. Results showed that controls had higher levels of IFN-gamma production than the MS patient groups and suggest that MS patients included in this study have a lower ability of immune system activation than HC. Results confirm that fingolimod is able to suppress production of IFN-gamma. The fact that the QFM score of MS patients is significantly lower than that of HC may indicate a dysfunctional state of the immune system in baseline conditions.

Citovat

PAVELEK, Zbysek, Ondrej SOUCEK, Jan KREJSEK, Ilona SEJKOROVA, Oldrich VYSATA, Blanka KLIMOVA, Francesco ANGELUCCI, Pavel ŠTOURAČ, Martin VALIS, Marek PETERKA, Lukas SOBISEK a Michal NOVOTNY. Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor. Journal of Immunology Research. London: Hindawi, 2023, roč. 2023, April 2023, s. 1-8. ISSN 2314-8861. Dostupné z: https://dx.doi.org/10.1155/2023/4653627.

@article{2368139,
   author = {Pavelek, Zbysek and Soucek, Ondrej and Krejsek, Jan and Sejkorova, Ilona and Vysata, Oldrich and Klimova, Blanka and Angelucci, Francesco and Štourač, Pavel and Valis, Martin and Peterka, Marek and Sobisek, Lukas and Novotny, Michal},
   article_location = {London},
   article_number = {April 2023},
   doi = {http://dx.doi.org/10.1155/2023/4653627},
   keywords = {Multiple Sclerosis; Immune System; QuantiFERON Monitor},
   language = {eng},
   issn = {2314-8861},
   journal = {Journal of Immunology Research},
   title = {Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor},
   url = {https://www.hindawi.com/journals/jir/2023/4653627/},
   volume = {2023},
   year = {2023}
}

TY  - JOUR
ID  - 2368139
AU  - Pavelek, Zbysek - Soucek, Ondrej - Krejsek, Jan - Sejkorova, Ilona - Vysata, Oldrich - Klimova, Blanka - Angelucci, Francesco - Štourač, Pavel - Valis, Martin - Peterka, Marek - Sobisek, Lukas - Novotny, Michal
PY  - 2023
TI  - Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor
JF  - Journal of Immunology Research
VL  - 2023
IS  - April 2023
SP  - 1-8
EP  - 1-8
PB  - Hindawi
SN  - 23148861
KW  - Multiple Sclerosis
KW  - Immune System
KW  - QuantiFERON Monitor
UR  - https://www.hindawi.com/journals/jir/2023/4653627/
N2  - Background. The QuantiFERON (R)-Monitor (QFM) is an assay that measures interferon-gamma production and was developed to provide an objective marker of complex immune response. In this study, we evaluated the use of the QFM test in patients with two forms of multiple sclerosis (MS), relapsing-remitting form treated with fingolimod (fMS) and secondarily progressive form not treated pharmacologically (pMS), and in healthy controls (HC). We hypothesized that IFN-gamma levels would be lower in those subjects who are relatively more immunosuppressed and higher in those with normal or activated immune function. Methods. This single-center observational study was conducted from November 2020 to October 2021 and compared results in three groups of patients: 86 healthy controls, 96 patients with pMS, and 78 fMS. Combination of lyophilized stimulants was added to 1 ml heparinized whole blood within 8 hr of collection. Plasmatic IFN-gamma was measured using the ELISA kit for the QFM and data were obtained in IU/ml. Results. The results showed that controls had nearly 2-fold higher levels of IFN-gamma (QFM score) in median (q25, q75) 228.00 (112.20, 358.67) than the MS patient groups: pMS 144.80 (31.23, 302.00); fMS 130.50 (39.95, 217.07) which is statistically significant difference P-value: HC vs. pMS = 0.0071; HC vs. fMS = 0.0468. This result was also confirmed by a validation analysis to exclude impact of variable factors, such as disease duration and Expanded Disability Status Scale scores. Conclusions. Results showed that controls had higher levels of IFN-gamma production than the MS patient groups and suggest that MS patients included in this study have a lower ability of immune system activation than HC. Results confirm that fingolimod is able to suppress production of IFN-gamma. The fact that the QFM score of MS patients is significantly lower than that of HC may indicate a dysfunctional state of the immune system in baseline conditions.
ER  -

PAVELEK, Zbysek, Ondrej SOUCEK, Jan KREJSEK, Ilona SEJKOROVA, Oldrich VYSATA, Blanka KLIMOVA, Francesco ANGELUCCI, Pavel ŠTOURAČ, Martin VALIS, Marek PETERKA, Lukas SOBISEK a Michal NOVOTNY. Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor. \textit{Journal of Immunology Research}. London: Hindawi, 2023, roč.~2023, April 2023, s.~1-8. ISSN~2314-8861. Dostupné z: https://dx.doi.org/10.1155/2023/4653627.

Podrobný výpis o publikaci